US 12,135,329 B2
Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
Jiang Wu, Lexington, MA (US); Guodong Zhang, Lexington, MA (US); Daniel J. Sexton, Melrose, MA (US); Ryan Faucette, Melrose, MA (US); Gul M. Mustafa, Morgantown, WV (US); and Mark Szewc, Morgantown, WV (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Apr. 28, 2023, as Appl. No. 18/308,813.
Application 18/308,813 is a division of application No. 16/062,734, granted, now 11,668,718, previously published as PCT/US2016/066936, filed on Dec. 15, 2016.
Claims priority of provisional application 62/267,734, filed on Dec. 15, 2015.
Prior Publication US 2023/0408528 A1, Dec. 21, 2023
Int. Cl. G01N 33/68 (2006.01); G01N 30/72 (2006.01); G01N 30/88 (2006.01); G01N 30/02 (2006.01)
CPC G01N 33/6848 (2013.01) [G01N 30/7233 (2013.01); G01N 30/88 (2013.01); G01N 33/6893 (2013.01); G01N 2030/027 (2013.01); G01N 2030/8831 (2013.01); G01N 2800/224 (2013.01); G01N 2800/50 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method for identifying a subject having or at risk for hereditary angioedema (HAE), the method comprising:
(i) providing a biological sample of a subject,
(ii) contacting the sample with a protease to generate a plurality of digested peptides;
(iii) measuring the level of a signature peptide in the plurality of digested peptides, wherein the signature peptide is indicative of the 46 kDa light chain and is KHNLGHGH (SEQ ID NO: 1), or the 56 kDa light chain and is SSRIGE (SEQ ID NO: 5); and
(iv) identifying the subject as having HAE or being at risk for HAE attack based on the level of cleaved HMWK, wherein an elevated level of cleaved HMWK in the biological sample as compared with a predetermined reference value indicates that the subject has HAE or is at risk for HAE attack.